Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Study of [14C]SHR2554 in Healthy Chinese Men
NCT06010680Phase 1Completed
- Sponsor
- Hengrui
- Start
- Oct 2023
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zeprumetostat in lymphoma, sponsored by Hengrui. Primary endpoints: Cumulative recovery and recovery rate of total radioactive substance in urine and feces, Percentage of parent drug and its metabolites in plasma as a percentage of total radioactive exposure (%AUC) and 8 more. Started Oct 2023; status: completed.
02
Drugs
zeprumetostat
03
Conditions
lymphoma
Beyond the preview
Go deeper on NCT06010680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06010680.